About Combined oxidative phosphorylation defect type 21
Combined oxidative phosphorylation defect type 21 is a rare disease catalogued by Orphanet (ORPHA:420733). It is associated with the TARS2 gene. Search below for active recruiting clinical trials from ClinicalTrials.gov, or visit the Orphanet expert page for specialist centres, natural history studies, and patient registries.
Clinical Trial Eligibility Tips
What to know before applying to Combined oxidative phosphorylation defect type 21 trials.
Search ClinicalTrials.gov for "Combined oxidative phosphorylation defect type 21" or filter by Orphanet code ORPHA:420733 to find disease-specific studies.
Ask your specialist to refer you to a Centre of Expertise — Orphanet lists all accredited centres for this condition worldwide.
Natural history studies and patient registries often enrol before drug trials open — contact the Orphanet patient community first.
Patient Resources
Find recruiting Combined oxidative phosphorylation defect type 21 trials
Search 500,000+ studies from ClinicalTrials.gov, filtered for Combined oxidative phosphorylation defect type 21. Updated daily.